[Research] Celltrion (068270) – DS Investment & Securities | 2Q26 Re: Steep Growth Exceeds Expectations · New Biosimilars Surge · Large-Cap Top Pick / 2026-07-28
Brokerage : DS Investment & Securities Analyst : Minjeong Kim Investment Rating : BUY (Maintained) & Large-Cap Top Pick Target Price : KRW 320,000 (Maintained) Core Momentum : Strong 2Q26 earnings beat driven by steep revenue growth from second-wave new biosimilars including Omlyclo and Eyptozma, with second-half catalysts including Omlyclo 300mg high-dose rollout and Pfizer-Zymfentra…